Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis
Allergol. immunopatol
; 51(3): 181-185, 01 mayo 2023. ilus, tab
Article
in English
| IBECS
| ID: ibc-219828
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Asthma
/
Dermatitis, Atopic
/
Antibodies, Monoclonal, Humanized
/
Hyperthyroidism
Limits:
Adolescent
/
Humans
/
Male
Language:
English
Journal:
Allergol. immunopatol
Year:
2023
Document type:
Article
Institution/Affiliation country:
Casa di Cura Villa Montallegro/Italy
/
IRCCS Giannina Gaslini/Italy